Bayh-Dole and the Coronavirus Crisis

Thursday, April 23, 2020 – 12:30 PM TO 1:45 PM EDT

Video Webinar

Event Summary

The world is anxiously awaiting effective treatments for Covid-19, which is ravaging most countries. Fortunately, some of the best minds in our public and private sectors are putting everything they have into developing effective vaccines, drugs, and tests that are so desperately needed. Because of the Bayh-Dole Act, which allows academic institutions and federal laboratories to effectively license their discoveries so they can make the leap from being laboratory concepts into useful products, these partnerships are proceeding at full speed. Unfortunately, some want to undo this model at the very time we need it the most.

This video webinar, co-hosted by the Bayh-Dole 40 Coalition and ITIF, delves into the critical role that partnerships between industry, academia, and federal labs will play in combating Covid-19, how these partnerships work, what risks they entail, why patents and licenses are so important in overcoming the risks inherent in developing drugs and vaccines, and how the Bayh-Dole Act enables the process for the benefit of people in the United States and around the world.

Follow @BayhDole40 on Twitter. 

Read the full transcript of the video webinar here.


Joseph P. Allen
Former President
National Technology Transfer Center
Wendy Commins Holman
CEO and Founder
Ridgeback Biotherapeutics
Mark Rohrbaugh
Special Advisor for Technology Transfer
National Institute of Health
Jon Soderstrom

Managing Director
University Technology Commercialization and Faculty Innovation, Yale University

Stephen Ezell
Vice President, Global Innovation Policy
Information Technology and Innovation Foundation